Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
9.64
-0.23 (-2.33%)
At close: Jul 15, 2026, 4:00 PM EDT
9.51
-0.13 (-1.35%)
After-hours: Jul 15, 2026, 7:38 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$989,491
Market Cap
706.33M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 17 | 44.74% |
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| REGENXBIO | 371 |
| CorMedix | 191 |
| Omeros | 175 |
| Allogene Therapeutics | 152 |
| Prime Medicine | 146 |
| BridgeBio Oncology Therapeutics | 106 |
| AgomAb Therapeutics NV | 62 |
CADL News
- 2 days ago - Candel Therapeutics initiated with a Buy at Stifel - TheFly
- 7 days ago - Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Candel Therapeutics Slides: Corporate presentation - Filings
- 14 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - GlobeNewsWire
- 20 days ago - Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - GlobeNewsWire
- 22 days ago - Candel Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts